Top Story

Ixazomib may provide more convenient, effective treatment for multiple myeloma

December 21, 2014

SAN FRANCISCO — Shaji K. Kumar, MD, professor of medicine at the Mayo Clinic in Rochester, Minn., discusses the experimental agent, ixazomib, which may provide patients with multiple myeloma with a more convenient treatment regimen.

Currently, the only available proteasome inhibitors are bortezomib (Velcade; Millennium) and carfilzomib (Kyprolis; Onyx) and they are can only be administered intravenously or through a subcutaneous injection.

Vosaroxin combination demonstrated improved survival in AML Meeting News CoverageVideo

Vosaroxin combination demonstrated improved survival in AML

December 20, 2014
SAN FRANCISCO — Farhad Ravandi, MD, professor of medicine in the department of leukemia at The University of Texas MD Anderson Cancer Center, discusses data from…

New next-generation sequencing test launched for thyroid nodules

December 20, 2014
Interpace Diagnostics, a molecular diagnostics subsidiary of PDI, Inc., has recently launched a new next-generation sequencing test designed to determine the difference…
In the Journals

ST2 levels predicted acute GVHD, mortality after double-unit cord blood transplantation

December 19, 2014
High levels of the biomarker suppressor of tumorigenicity 2 at 28 days post-cord blood transplantation independently predicted acute graft-versus-host disease, according…
In the Journals

Anticoagulant, antiplatelet medications carry rare dermatologic surgery hemorrhage risks

December 19, 2014
Dermatologists and dermatologic surgeons should be aware of the bleeding risks of anticoagulant and antiplatelet drugs used for cardiovascular diseases, according to…
More News Headlines »
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »
Meeting News Coverage Video
thumbnail for video 3949008667001

Data show encouraging advances in treatment of AML

December 17, 2014
SAN FRANCISCO – According to preliminary data presented at the ASH Annual Meeting and Exposition, FLT3 inhibitors…
More »
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »